Effects of concomitant administration of DPP-4 and SGLT2 inhibitors in Japanese patients with type 2 diabetes

Effects of concomitant administration of DPP-4 and SGLT2 inhibitors in Japanese patients with type 2 diabetes - Effects of concomitant administration of DPP-4 and SGLT2 inhibitors in Japanese patients with type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026442

Enrollment

220

Registered

2017-03-07

Start date

2015-03-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Administration of SGLT2 inhibitor (luseogliflozin 2.5 mg q.d., dapagliflozin 5 mg q.d., tofogliflozin 20 mg q.d., empagliflozin 10 mg q.d., or canagliflozin 100 mg q.d.) for 6 months Concomitant admin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients. Obtained written informed consent from the patients before participation.

Exclusion criteria

Exclusion criteria: Having severe nephropathy.

Design outcomes

Primary

Measure	Time frame
Body mass index, HbA1c, plsma total cholesterol, HDL and LDL cholesterol, triglyceride, AST, ALT, and gamma-GTP levels at 6 months after the start of drug treatment	—

Secondary

Measure	Time frame
Plasma uric acid level at 6 months after the start of drug treatment	—

Countries

Japan

Contacts

Public ContactMasataka Kusunoki

Nagoya University Research Center of Health, Physical Fitness and Sports

info@tonyo.jp052-789-3946

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026